| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.1993.03510180065035 |
| P698 | PubMed publication ID | 8411602 |
| P50 | author | Meir J. Stampfer | Q80164992 |
| Charles H Hennekens | Q89527500 | ||
| Paul Ridker | Q7153226 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| LPA | Q18028636 | ||
| lipoprotein | Q28350 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 2195-2199 | |
| P577 | publication date | 1993-11-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | A prospective study of lipoprotein(a) and the risk of myocardial infarction | |
| P478 | volume | 270 |
| Q42953645 | A Multimarker Approach for the Prediction of Coronary Artery Disease: Cost-Effectiveness Analysis |
| Q53154011 | A unique pattern of apo(a) polymorphism in an isolated east Greenlandic Inuit (Eskimo) population. |
| Q33751628 | AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology |
| Q73364939 | Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors |
| Q40482679 | An update on coronary risk factors |
| Q35796463 | Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. |
| Q51552231 | Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. |
| Q43919582 | Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). |
| Q36449485 | Association study of lipoprotein(a) genetic markers, traditional risk factors, and coronary heart disease in HIV-1-infected patients. |
| Q37552536 | Atherosclerotic risk among children taking antiepileptic drugs |
| Q36593266 | Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease |
| Q70930163 | Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs |
| Q73111112 | Characterization of the genetic elements controlling lipoprotein(a) concentrations in Mexican Americans. Evidence for at least three controlling elements linked to LPA, the locus encoding apolipoprotein(a) |
| Q73965127 | Clinical implications of elevated lipoprotein(a) |
| Q71955932 | Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation |
| Q64930565 | Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). |
| Q37130840 | Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. |
| Q71814226 | Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay |
| Q30437424 | Effects of renal replacement therapy on plasma lipoprotein(a) levels |
| Q73597780 | Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels |
| Q39469427 | Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion |
| Q74530447 | Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris |
| Q35170825 | Established and recently identified coronary heart disease risk factors in young people: the influence of physical activity and physical fitness |
| Q41666481 | Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element |
| Q72648860 | Familial Hypercholesterolaemia Regression Study and its implications |
| Q52881005 | Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. |
| Q74595429 | Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels |
| Q40436410 | Genetic Determinants of Myocardial Infarction |
| Q35643684 | Genetic variation in lipoprotein (a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein (a) gene locus. |
| Q71125983 | Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men |
| Q38297505 | Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). |
| Q41289982 | Inhibitors for the In Vitro Assembly of Lp(a) |
| Q74314734 | Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study |
| Q72306457 | Is there anything to add to our lipid risk factors for coronary heart disease? |
| Q55652029 | LDL-apheresis: technical and clinical aspects. |
| Q41808457 | LP(a) phenotypes and levels in angiographically proven coronary heart disease patients and controls |
| Q41719630 | Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women |
| Q33835341 | Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial |
| Q41470502 | Lifestyle, fibrinolysis and lipids |
| Q50954943 | Lipid abnormalities in Greek patients with coronary artery disease. |
| Q72053259 | Lipoprotein (a) and vascular disease in diabetic patients |
| Q30242031 | Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology |
| Q31817214 | Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. |
| Q36731801 | Lipoprotein (a) measurements for clinical application |
| Q40964818 | Lipoprotein (a). |
| Q74595426 | Lipoprotein (a): a controversial risk factor for atherosclerotic heart disease |
| Q39002143 | Lipoprotein (a): a historical appraisal |
| Q34078108 | Lipoprotein Lp(a) and atherothrombotic disease. |
| Q35182567 | Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study |
| Q57273953 | Lipoprotein(a) Serum Levels and Vascular Diseases in an Older Caucasian Population Cohort |
| Q74635708 | Lipoprotein(a) and coronary thrombosis and restenosis after stent placement |
| Q28303150 | Lipoprotein(a) and risk of myocardial infarction--genetic epidemiologic evidence of causality |
| Q77896432 | Lipoprotein(a) as a risk factor for coronary artery disease |
| Q43762325 | Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemia |
| Q35737842 | Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality |
| Q51587807 | Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Québec Cardiovascular Study) |
| Q44114964 | Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). |
| Q32054940 | Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk |
| Q21284797 | Lipoprotein(a) in cardiovascular diseases |
| Q41300659 | Lipoprotein(a) in health and disease |
| Q73662507 | Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm |
| Q24669902 | Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits |
| Q73746087 | Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation |
| Q28282665 | Lipoprotein(a) should be taken much more seriously |
| Q74273275 | Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men |
| Q39033744 | Lipoprotein(a)-clinical aspects and future challenges |
| Q91684402 | Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction |
| Q36232356 | Lipoprotein(a): implications for clinical practice |
| Q40568220 | Lipoprotein(a): new insights into an atherogenic lipoprotein |
| Q35799761 | Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. |
| Q38045424 | Lipoprotein(a): resurrected by genetics |
| Q35585949 | Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation |
| Q73857185 | Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (RE |
| Q33822162 | Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a) |
| Q35052188 | New paradigms in preventive cardiology: unconventional coronary risk factors |
| Q46405626 | No Association Between Plasma Lipoprotein(a) Concentrations and the Presence or Absence of Coronary Atherosclerosis in African-Americans |
| Q37140097 | Novel markers of inflammation in atherosclerosis. |
| Q91188032 | Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease |
| Q33740239 | Pathogenesis and pathology of coronary heart disease syndromes |
| Q73245485 | Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels |
| Q40872170 | Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. |
| Q46825446 | Plasma homocysteine and lipoprotein (a) levels in Turkish patients with metabolic syndrome |
| Q57193293 | Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease |
| Q35559549 | Plasma lipoprotein concentrations in ethnic populations |
| Q33857984 | Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors |
| Q39148923 | Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a). |
| Q71878215 | Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome |
| Q73318670 | Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men |
| Q44091469 | Relation of high lipoprotein(a) to other traditional atherosclerotic risk factors in patients with coronary heart disease |
| Q34002189 | Relook at lipoprotein (A): independent risk factor of coronary artery disease in north Indian population |
| Q71606947 | Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women |
| Q82572967 | Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy |
| Q46792170 | Serum lipid and apolipoprotein profiles in newborns and six-year-old children: the Tallinn Young Family Study |
| Q36824175 | Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction |
| Q38807488 | Structure, function, and genetics of lipoprotein (a). |
| Q73200642 | Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men |
| Q48751421 | Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. |
| Q33685763 | The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. |
| Q49101307 | Tracking of serum lipoprotein (a) concentration and its contribution to serum cholesterol values in children from 7 to 36 months of age in the STRIP Baby Study. Special Turku Coronary Risk Factor Intervention Project for Babies |
| Q40950575 | Trans fatty acids: implications for health, analytical methods, incidence in edible fats and intake (a review). |
| Q58071851 | Urinary apo(a) discriminates coronary artery disease patients from controls |
| Q73540801 | [Genetic risk factors for myocardial infarct] |
| Q74219025 | [Lipoprotein (a) as a predictor of severity of coronary artery stenosis documented by angiography in male coronary patients under 50 years old] |
| Q53614132 | [Lipoprotein(a): influence on cardiovascular manifestation]. |
Search more.